Background and Purpose-There were limited data on the long-term outcome of patients with symptomatic intracranial atherosclerotic stenosis Ն70% after Wingspan stenting. Using our Wingspan cohort data and the data from the Warfarin and Aspirin for Symptomatic Intracranial Atherosclerotic Disease (WASID) as a historical control, we tested the hypothesis that stenting provided no benefit over antithrombotic therapy alone for these high-risk patients. Methods-Between January 2007 and February 2009, 100 consecutive patients with intracranial atherosclerotic stenosis Ն70% and symptoms within 90 days were enrolled into this prospective single-center Wingspan cohort study and followed up until the end of February 2010. Stenosis was measured per the WASID criteria. One-year risk of primary end point (any stroke or death within 30 days and ipsilateral ischemic stroke afterward) was compared with that of ipsilateral ischemic stroke in the WASID patients with Ն70% stenosis. Results-The stent placement success rate was 99%. All patients but 1 had clinical follow-up of Ն12 months. During a mean follow-up of 1.8 years, 9 patients developed primary end point events (5 within 30 days and 4 afterward). The 1-year risk of the outcome events was lower than that in similar WASID patients: 7.3% (95% CI, 2.0% to 12.5%) versus 18% (95% CI, 13% to 24%; PϽ0.05).
T he Warfarin and Aspirin for Symptomatic Intracranial
Atherosclerotic Disease (WASID) trial showed that patients with symptomatic intracranial arterial stenosis (ICAS) Ն70% are at particularly high risk of recurrent stroke at the time of being on medical therapy. 1, 2 There has been increased enthusiasm for the use of Wingspan stents (Boston Scientific) to treat these high-risk patients in recent years. [3] [4] [5] However, there were limited data on long-term outcome after this aggressive therapy. In a multicenter registry, Wingspan stenting seemed to have no advantage compared with medical therapy. 3 However, the study showed a significantly lower stroke rate in high-volume centers versus low-volume centers.
The Stenting and Aggressive Medical Management for the Prevention of Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial is currently in progress comparing aggressive medical management alone with medical management plus Wingspan stenting in patients who have a 70% to 99% ICAS and a qualifying event within 30 days. 6 The trial is anticipated to be completed by 2013. Until then, physicians and patients are in a quandary when making a decision on Wingspan stenting.
Using our Wingspan cohort data and the WASID data as historical controls of medical therapy, we tested the hypothesis that Wingspan stenting provided no benefit over antithrombotic therapy alone for high-risk ICAS patients.
Materials and Methods

Subjects
The protocol for this prospective single-center Wingspan study was approved by our institutional ethics committee. Written informed consent was obtained from all patients. Patient demographics, atherosclerotic risk factors, clinical data, images, and follow-up information were prospectively collected.
Inclusion criteria included angiographically verified Ն70% stenosis of a major intracranial artery that caused transient ischemic attack (TIA) or minor ischemic stroke (National Institutes of Health Stroke Scale score Ͻ9) within 90 days; lesion length Ͻ15 mm and normal arterial diameter adjacent to the stenosis between 2.0 and 4.5 mm; 18 to 75 years of age; and at least 1 atherosclerotic risk factor (arterial hypertension, diabetes mellitus, hyperlipidemia, and cigarette smoking).
Exclusion criteria included nonatherosclerotic stenosis; intracranial hemorrhage in the territory of the stenotic artery within 6 weeks; potential source of cardiac embolism; concurrent intracranial tumor, aneurysm, or cerebral arteriovenous malformation; known contraindication to heparin, aspirin, clopidogrel, anesthesia, or contrast media; hemoglobin level Ͻ10 g/dL, platelet count Ͻ100 000 per microliter, international normalized ratio Ͼ1.5 (irreversible) and uncorrectable bleeding diathesis; and life expectancy Ͻ1 year because of other medical conditions. Patients with multiple intracranial stenoses or concomitant tandem stenosis Ն50% of the extracranial artery were not excluded from this study.
Between January 2007 and February 2009, 113 consecutive patients with symptomatic ICAS Ն70% underwent Wingspan stenting at our institute. One hundred patients with 105 lesions were treated within 90 days of the qualifying event. Thirteen patients with 13 lesions were excluded due to being stented Ͼ90 days after the qualifying event. Four of the 100 enrolled patients had multiple high-grade intracranial stenoses (3 with 2 lesions and 1 with 3 lesions), and 7 had concomitant tandem stenosis Ն50% in the extracranial carotid (nϭ3) or vertebral (nϭ4) artery. The multiple stenoses and the tandem extracranial lesion were also stented during the procedure.
End Point Assessment
National Institutes of Health Stroke Scale score and modified Rankin Scale score during hospitalization and end point events after enrollment were independently assessed by stroke neurologists. The primary end point was any stroke or death within 30 days and ipsilateral ischemic stroke afterward. The secondary end point included ischemic stroke outside of the territory of the stented artery, hemorrhagic stroke, and nonstroke death beyond 30 days; emergency cerebral artery revascularization without sequela; TIA in the territory of the stented artery; and other major hemorrhages at any time. 7 Definitions of the events are shown in the Supplemental materials (http://stroke.ahajournals.org).
Periprocedural Management, Stenting Procedure, and Follow-Up
Brain MRI, CT perfusion imaging, and cerebral angiography were completed 1 to 7 days before stent placement. Stenosis was measured manually and blindly by a radiologist per the WASID criteria. 8 The protocol of antiplatelet therapy was prespecified as follows: 300 mg aspirin plus 75 mg clopidogrel daily for Ն3 days before the operation and for at least 1 month after stenting and then either 100 to 300 mg aspirin or 75 mg clopidogrel for life. 3, 4 Modifiable atherosclerotic risk factors were also managed after enrollment.
The procedure was performed under local (nϭ97) or general anesthesia (nϭ3) by an experienced interventional neuroradiologist (W.J.J. or B.D.). Intravenous infusion of nimodipine (0.6 mg/hr; Bayer AG) was started 2 hours before the procedure to prevent vasospasm. Intravenous heparin was administered after placement of a 6-Fr sheath into the femoral artery as a bolus of 3000 U followed by 800 U/hr based on the protocol described in a previous study on intracranial stenting for a Chinese population. 9 The study showed an activated clotting time of 245Ϯ65 seconds (range, 161 to 394 seconds), which was very close to the 250-to 300-second target used in the National Institutes of Health registry and US multicenter study. 3,5 A 6-Fr guiding catheter was then advanced into the distal cervical vertebral or internal carotid artery. Using the guiding catheter as a reference, a quantitative angiogram for sizing a Gateway balloon (Boston Scientific) and Wingspan stent was performed as described previously (http://stroke.ahajournals.org). 10 Under roadmap guidance, an assembly of a microcatheter and a 300-cm microwire was carefully steered through the target lesion to its distal segment. After the microcatheter was removed, the Gateway balloon was advanced over the microwire, centered across the lesion, and inflated slowly to 6 to 8 atmospheric pressure. Angiography was repeated before removal of the balloon. The Wingspan stent delivery system was advanced over the microwire across the target lesion followed by deployment of the stent and removal of the delivery catheter. Stent placement success was defined as complete coverage of the target lesion with the stent resulting in Ͻ50% residual stenosis and good anterograde blood flow.
The patient's blood pressure was kept within 100 to 120/60 to 80 mm Hg with intravenous nimodipine or urapidil hydrochloride (ALTANA Pharma AG) to prevent hyperperfusion syndrome. Brain CT was performed postprocedurally to evaluate intracerebral hemorrhage.
After stenting, all patients were given a weight-based dose of 0.4 to 0.6 mL Fraxiparine (Sanofi Winthrop Industrie) every 12 hours subcutaneously for 3 days and monitored until discharge. After discharge, they had follow-up visits at 30 days. Subsequent followups were completed by clinic visits or by telephone until the end of February 2010. Their modified Rankin Scale score at the last contact date was evaluated by stroke neurologists or a trained nurse. Brain MRI or CT was performed if patient had a new neurological event.
Follow-up angiography was scheduled after 6 months on a voluntary basis or when restenosis was suspected clinically. In-stent restenosis was defined as an angiographically verified Ն50% stenosis within the stent or at the edge of the stent in the range of 3 mm.
Historical Control of Medical Therapy
The WASID data were used as a historical control of medical therapy. In the WASID subgroup of 206 patients with Ն70% intracranial stenosis, 40 (19%) developed ipsilateral ischemic stroke during follow-up of 1.8 years despite antithrombotic therapy. 2 The cumulative probability of the stroke was 18% (95% CI, 13% to 24%) at 1 year. 3 
Statistical Analysis
All data were analyzed according to the intention-to-treat principle. The patient characteristics, angiographic outcomes, and clinical outcomes were presented as meanϮSD for continuous variables or median and interquartile range for continuous variables that had skewed distributions or as percentages for nominal variables. Using 2 or Fisher exact test (when the expected cell frequency was Ͻ5), we compared the percent of patients with good control of each risk factor at baseline versus last follow-up. Reported probability values were 2-sided, and probability values Ͻ0.05 were considered significant. Cumulative probability of primary end point events over time was estimated by the product-limit method with a 95% CI at 1 year and 2 years. The probability at 1 year was compared with that of the ipsilateral ischemic stroke in the WASID patients with Ն70% stenosis. Lack of overlap in the 95% CI was considered having statistical significance.
Results
Baseline Characteristics and Procedural Outcome
The 100 patients underwent elective stenting after clopidogrel and aspirin therapy for 11.1Ϯ5.3 days (median, 10 days; range, 3 to 40 days). The stenting was performed at 33.6Ϯ22.3 days (median, 29.5 days) from the qualifying event. Tables 1 and 2 summarize patient and lesion characteristics and angiographic outcomes after stenting. A representative case is shown in the Supplemental materials. The stent placement success rate was 99% (99 of 100 patients or 104 of 105 lesions). It failed in 1 patient because the Wingspan stent system could not be delivered to the site distal to the basilar artery stenosis after successful balloon predilatation. In this cohort, no patient underwent postdilatation with balloon after placement of the Wingspan stent, and the median time from stenting to discharge was 5 days (interquartile range, 4 to 7 days).
Primary End Point
In this cohort, no one was lost to follow-up. One patient died of ipsilateral stroke 8 months after stenting. Other patients had clinical follow-up of Ն12 months. During a mean follow-up time of 21.4Ϯ8.2 months (median, 20.9 months), we observed 9 (9%) primary end point events (see Supplemental materials): 5 (5%) within 30 days (3 ischemic strokes and 2 intracerebral hemorrhages) without fatality and 4 (4%) after 30 days. Eight of the 9 events occurred in patients with single intracranial stenosis treated with a stent and 1 in a patient with concomitant tandem stenosis of an extracranial artery. The cumulative probability of primary end point (Figure) was 7.3% (95% CI, 2.0% to 12.5%) at 1 year, which was lower than the 18% (95% CI, 13% to 24%) risk of 1-year ipsilateral ischemic stroke in similar WASID patients (PϽ0.05).
Secondary End Point
We also observed 15 secondary end point events. Nine occurred within 30 days, including 7 TIAs (5 in the posterior circulation and 2 in the anterior circulation) and 2 emergency cerebral artery revascularizations. Six patients experienced TIA in the territory of the stented artery after 30 days. Five of them had catheter angiography, which revealed 4 (80%) in-stent restenoses. All of these events occurred in patients treated with a Wingspan stent, but 1 was a TIA and occurred intraoperatively in 1 patient with intracranial vertebral stenosis and concomitant tandem lesions of the intracranial and extracranial carotid artery.
In-Stent Restenosis
Forty-five stented vessels in 44 patients were evaluated by catheter angiography at a mean of 8.6 months (median, 7.2 months). The in-stent restenosis rate was 26.7% (12 of 45), and the symptomatic restenosis rate was 11.1% (5 of 45).
Pharmacological Therapy for Antiplatelet and Risk Factor Management
After stenting, all patients were treated with both aspirin and clopidogrel for 3 to 36 months, but 2 patients suspended clopidogrel therapy for 1 day or 30 days due to periprocedural intracerebral hemorrhage. Table 3 shows the percent of patients with good control of each risk factor at baseline versus last follow-up.
Outcome of Patients Who Were Excluded From This Study
We observed 1 secondary end point event (TIA) after 30 days and no primary end point event during a mean follow-up of 23.5Ϯ7.7 months (median, 25 months) in the 13 patients who were not included into this study. The catheter angiogram follow-up was performed in 6 of the 13 patients at a median of 9.5 months (11.3Ϯ5.5 months). It revealed 1 restenosis (16.7% [1 of 6]), which was symptomatic.
Discussion
The clinical outcome of Wingspan stenting for patients with ICAS Ն70% and symptoms within 90 days in this single high-volume center study compares favorably with that of antithrombotic therapy alone in similar patients of the WASID study. 2, 3 Of note, our cohort included 11 (11%) patients with multiple intracranial stenoses or tandem extracranial stenosis, representing a "real-world" setting in clinical practice. These patients may be at higher risk of recurrent stroke on medical therapy than those with single ICAS. 11 However, 10 of the 11 patients had not experienced a primary end point event after stenting. 
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The favorable outcome in this cohort is probably due to the low 30-day rate of stroke or death (5%). So far, there have been 3 published multicenter Wingspan studies. Two of them showed a similarly low rate of 30-day stroke or death at 4.5% and 6.4%, respectively. 4, 5 However, the other study reported a 9.3% risk of periprocedural major complication in patients with ICAS Ն70%, 3 mainly due to a much higher complication rate at the low-volume centers (17.2%) as compared with the high-volume center (6.8%). 3 Similarly, results from INTRASTENT, the European multicentric registry for stent treatment of intracranial stenoses in 372 patients, showed a 7% risk of major periprocedural complications. 12 The favorable outcome might also be related to more aggressive medical treatment or better control of blood pressure and cholesterol in this cohort patients than the WASID patients. 1, 13 Warfarin or a high dose of aspirin (1300 mg) was used in the WASID patients, 1 whereas our patients were treated with dual antiplatelet agents for Ն3 months followed by an antiplatelet agent during follow-up. In the WASID patients, only 82% took a statin at any time during the trial (versus 99% in our patients). The proportion of patients with hypertension who were on an angiotensinconverting enzyme inhibitor at any time was similar (67% versus 72%), and the proportion of patients with diabetes who were treated with insulin or an oral hypoglycemic agent at any time was also similar (91% versus 97%). Among WASID patients who had 2-year follow-up, 53% had systolic blood pressure Ͻ140 mm Hg (versus 65% in our cohort), 56% had low-density lipoprotein Ͻ100 mg/dL (versus 81%), or 79% had cholesterol Ͻ200 mg/dL (versus 89%). However, in the WASID patients, there was better control of cigarette smoking: only 16% remained smoking (versus 41%); and control of blood sugar was also better for those with diabetes at baseline: 52% had hemoglobin A1C Ͻ7% or fasting blood glucose Ͻ6.1 mmol/L (versus 41%). 13 The 4% risk of ipsilateral ischemic stroke beyond 30 days of Wingspan stenting in this cohort was within the range of 3.1% to 4.4% reported in other Wingspan studies with a mean follow-up of 6 or 13 months. 3, 4 A previous study with balloon-expandable stents also showed a low (3.3%) rate of ipsilateral ischemic stroke beyond 30 days. 7 These findings indicate that the rate of ipsilateral ischemic stroke after 30 days of ICAS stenting is low and relatively constant, and the most important quality control in clinical practice or trials of ICAS stenting is to reduce periprocedural major complications. In addition to stenting skills and experience of the operators, preprocedural evaluation, management of comorbidities and risk factors, and periprocedural care should be optimized to warrant the benefit of intracranial stenting.
There are some limitations in this study. First, the WASID data were used as a historical control to estimate the stenting benefit. Despite the fact that the WASID was a well-done randomized trial, using the WASID data as a control may import additional variability. In addition, the medical treatment of ICAS patients in our days is not the same as it was in the WASID trial, especially regarding the use of antiplatelets, statins, and blood pressure control. Second, the restenosis rate may be overestimated, because catheter angiography follow-up was performed on a voluntary basis or when The cumulative probability of ipsilateral stroke after 30 days plus any stroke or death within 30 days was 7.3% (95% CI, 2.0% to 12.5%) at 1 year and 9.6% (95% CI, 0.0% to 19.2%) at 2 years. 
